Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (731)	2/21/2002 7:27:04 PM
From: scaram(o)uche	Respond to of 1833

I occasionally post to the thread re. adenosine receptors, and the enormous markets that receptor subtype-specific molecules address. As OSIP has turned to talking almost exclusively of "oncology", I've drooled at the thought of regaining rights to some of the non-Solvay stuff. Big deal for a platform license, recently. Positive recent commentary re. asthma from Goddard. Selling for well below cash, wouldn't it be great if OSIP were in a position -- given their new passion for all things oncology -- to facilitate a [Cadus shareholder's] fantasy? But now to something more approximating reality...... "Hey, Russell, didn't we own a piece of another biotech? Kafus, or something like that? What happened to them?" :-) And, as you know, it's not wise to buy on the basis of a potential buyout. Yes, I've considered that he might do that. There is good leverage in Cadus, and IMO he'd be silly not to try to capture it. If he could buy a framework (Imclone) cheap, and fill it with cheap but good projects?

To: Tomato who wrote (731)	2/28/2002 1:29:38 PM
From: Tomato	Read Replies (2) \| Respond to of 1833

Misc. ramblings: 1. Woler made $307,500 in 1999 and a per annum of $300,000 in 1998 (started in Oct. '98 and made $125k that year and $110k in 2000 before Glass came on board). 2000 annual report, p. 26 Probably wouldn't significantly impact KDUS's financials to get a new CEO whose job was to liquidate the company for a good price, or perhaps buy an oil and gas company with the cash to take advantage of the tax loss carryovers (I hope not on the later possibility. If I recall correctly, the tax losses seemed to be a major rationale used by the Board for not distributing excess cash - with Berg partially buying in on that theory in his statement in support of SH proposal -- seems like most people on this thread don't give much weight to that asset). 2. If I'm reading it correctly, there are 437,070 shares subject to stock options, or about 3.3% of the 13.1 mil. shares out there. 200 annual report, p. 28 3. Will Glass's departure be a catalyst, or does Icahn consider KDUS like a pimple on an elephant's ass (or should that me "as a pimple on an elephant's ass?"[g])? 4. Do major SHs BMY, Physica, and Smith Kline care enough to do anything about the situation, or do they not give an elephant's pimple? 5. Will there be a greater likelihood that a new CEO will return SHs' phone calls? [g] 6. How much effort was Glass actually making in the past year to acquire another company or sell KDUS? He did have other things to do. 7. Has the value of KDUS increased, decreased, or stayed the same in the last few months?